J. Mcintyre, J. Castaǹer, R. Castañer
2004
Citations
0
Influential Citations
3
Citations
Journal
Drugs of The Future
Abstract
Reactive oxygen species released by activated neutrophils are involved in the inflammatory response of tissues, and thus have a role in the pathogenesis of such diverse diseases as ulcerative colitis and chronic obstructive pulmonary diseass (COPD), among others. Tetomilast inhibits superoxide production by human neutrophils, and also has phosphodiesterase type 4 (PDE4)-inhibitary activity. The protective effects of tetomilast have been demanstreted in a lumbar of models, including sepsis-induced lung injury and myocardial ischemia/repertusion-induced damage in pigs. Suppression of superoxide and TNF-α production from hepatic macrophages in rats was observed, and multiple inhibitory actions of tetormitest on leukocyte activation have been confirmed in vitro. The preliminary safety and efficacy of tetamilast have been demonstrated in mild to maderately active ulcerative colitis, with greater efficacy observed in patients with more severe disease at baseline. Tetomilast is in phase III clinical studies for ulserative colitis, as well as phase II clinical trials for COPD.